Madrigal Pharmaceuticals (MDGL) Change in Account Payables (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Change in Account Payables data on file, last reported at $3.6 million in Q1 2026.

• On a quarterly basis, Change in Account Payables rose 332.27% year-over-year to $3.6 million in Q1 2026; TTM through Mar 2026 was $10.4 million, a 59.24% decrease from a year earlier, with the FY2025 full-year figure at $5.3 million, down 66.07% from the prior year.
• Change in Account Payables for Q1 2026 stood at $3.6 million, down from $4.9 million in the prior quarter.
• Over the last five years, Change in Account Payables for MDGL reached as high as $37.0 million in Q3 2024 and fell as low as -$11.7 million in Q1 2023.
• Historically, Change in Account Payables has averaged $1.8 million across 5 years, with a median of $1.4 million in 2022.
• Across the five-year window, Change in Account Payables tumbled 935.93% in 2023 and jumped 3827.02% in 2024, its largest moves.
• Year by year, Change in Account Payables stood at $5.3 million in 2022, then surged by 118.24% to $11.5 million in 2023, then plunged by 120.58% to -$2.4 million in 2024, then jumped by 308.79% to $4.9 million in 2025, then retreated by 27.48% to $3.6 million in 2026.
• Per Business Quant data, the three most recent Change in Account Payables figures were $3.6 million in Q1 2026, $4.9 million in Q4 2025, and $6.0 million in Q3 2025.